SG11202106912WA - Anti-ephrin-b2 blocking antibodies for the treatment of fibrotic diseases - Google Patents
Anti-ephrin-b2 blocking antibodies for the treatment of fibrotic diseasesInfo
- Publication number
- SG11202106912WA SG11202106912WA SG11202106912WA SG11202106912WA SG11202106912WA SG 11202106912W A SG11202106912W A SG 11202106912WA SG 11202106912W A SG11202106912W A SG 11202106912WA SG 11202106912W A SG11202106912W A SG 11202106912WA SG 11202106912W A SG11202106912W A SG 11202106912WA
- Authority
- SG
- Singapore
- Prior art keywords
- ephrin
- treatment
- fibrotic diseases
- blocking antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4842—Monitoring progression or stage of a disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves
- A61B5/055—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Surgery (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862785873P | 2018-12-28 | 2018-12-28 | |
PCT/US2019/068746 WO2020140036A1 (fr) | 2018-12-28 | 2019-12-27 | Anticorps bloquant anti-b2 d'éphrine pour le traitement de maladies fibreuses |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202106912WA true SG11202106912WA (en) | 2021-07-29 |
Family
ID=71127301
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202106912WA SG11202106912WA (en) | 2018-12-28 | 2019-12-27 | Anti-ephrin-b2 blocking antibodies for the treatment of fibrotic diseases |
Country Status (8)
Country | Link |
---|---|
US (1) | US20220064285A1 (fr) |
EP (1) | EP3902460A4 (fr) |
JP (1) | JP2022516611A (fr) |
KR (1) | KR20210110326A (fr) |
AU (1) | AU2019414947A1 (fr) |
CA (1) | CA3125160A1 (fr) |
SG (1) | SG11202106912WA (fr) |
WO (1) | WO2020140036A1 (fr) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2659517T3 (es) * | 2007-05-30 | 2018-03-16 | Xencor, Inc. | Métodos y composiciones para inhibir células que expresan CD32B |
WO2008156642A1 (fr) * | 2007-06-15 | 2008-12-24 | Vasgene Therapeutics, Inc. | Échafaudages de liaison antigène non-immunoglobuline pour inhiber l'angiogenèse et la croissance tumorale |
ES2378976B1 (es) * | 2010-09-21 | 2013-05-06 | Fundación Centro Nacional De Investigaciones Oncológicas (Cnio) | Anticuerpo contra ephrin b2 y su uso. |
WO2013165590A1 (fr) * | 2012-05-03 | 2013-11-07 | Fibrogen, Inc. | Méthodes de traitement de la fibrose pulmonaire idiopathique |
AU2016301113B2 (en) * | 2015-07-30 | 2019-10-03 | Monash University | Fibrotic treatment |
-
2019
- 2019-12-27 KR KR1020217023282A patent/KR20210110326A/ko unknown
- 2019-12-27 SG SG11202106912WA patent/SG11202106912WA/en unknown
- 2019-12-27 CA CA3125160A patent/CA3125160A1/fr active Pending
- 2019-12-27 WO PCT/US2019/068746 patent/WO2020140036A1/fr unknown
- 2019-12-27 US US17/418,343 patent/US20220064285A1/en active Pending
- 2019-12-27 EP EP19903833.2A patent/EP3902460A4/fr active Pending
- 2019-12-27 JP JP2021537788A patent/JP2022516611A/ja active Pending
- 2019-12-27 AU AU2019414947A patent/AU2019414947A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2022516611A (ja) | 2022-03-01 |
KR20210110326A (ko) | 2021-09-07 |
CA3125160A1 (fr) | 2020-07-02 |
US20220064285A1 (en) | 2022-03-03 |
EP3902460A4 (fr) | 2023-01-11 |
EP3902460A1 (fr) | 2021-11-03 |
AU2019414947A1 (en) | 2021-07-15 |
WO2020140036A1 (fr) | 2020-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL279260A (en) | KDM1A inhibitors for the treatment of diseases | |
GB201804514D0 (en) | Treatment of pyroptosis | |
IL281449A (en) | Anti-ifnar1 antibodies for the treatment of autoimmune diseases | |
SG11202006374VA (en) | Treatment of demyelinating diseases | |
ZA201906213B (en) | Compounds and methods for the treatment of parasitic diseases | |
IL268357A (en) | Photoreceptor cells for the treatment of retinal diseases | |
IL277861A (en) | Antibodies specific to AXL for cancer treatment | |
IL274766A (en) | Human anti-LIV1 antibodies for the treatment of breast cancer | |
IL276482A (en) | Compounds for pain management | |
IL272937A (en) | Preparations and methods for the treatment of diseases involving fibrosis | |
EP3630101A4 (fr) | Méthodes de traitement de maladies | |
GB201813876D0 (en) | Treatment | |
SG11202011117VA (en) | Treatment of cancer | |
IL281792A (en) | Treatment methods | |
GB201804515D0 (en) | Treatment of necroptosis | |
GB201800546D0 (en) | Treatment | |
GB202015959D0 (en) | Treatment of diseases involving NAD | |
ZA202104357B (en) | Monoclonal antibodies against the beta chain region of human trbv9 | |
SG11202011434SA (en) | Methods for the treatment of bladder cancer | |
EP3735423A4 (fr) | Anticorps monoclonal néo-201 pour le traitement des carcinomes humains | |
GB201805100D0 (en) | Treatment of sarcopenic diseases | |
GB201808575D0 (en) | Methods for the treatment of psoriatic arthrits | |
EP3958754C0 (fr) | Dispositif pour le traitement de la maladie hemorroïdaire | |
IL282360A (en) | Treatment for neurological diseases | |
SG11202106912WA (en) | Anti-ephrin-b2 blocking antibodies for the treatment of fibrotic diseases |